Mutabilis will be represented at the European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) in Vienne from April 22nd to 25th 2017.
The AIDS pandemic is a major public health problem. In fact, the number of people living with HIV is estimated at around 33.2 million, mostly in sub-Saharan Africa. With the introduction of the tri-therapy – a combination therapy of at least three drugs with different mechanisms of action – the HIV infection has become a chronic disease that requires lifelong treatment.
The increasing prevalence of resistance to antibiotic undermines the effectiveness of the compounds currently present on the market. In Europe, 25,000 patients die each year from nosocomial infections caused by bacteria resistant to treatment¹. Since 1970, the majority of antibiotics on the market comes from the same chemical² scaffolds.
Founded in 2001, MUTABILIS is a spin-off of INSERM, based on the work of Professor Xavier Nassif’s team, pioneer in the identification of virulence genes in the Neisseria Meningitidis. These studies were then transposed to all Gram – bacteria, then to Gram+ bacteria.